Audio Only

Objectives
Inflammatory Bowel Disease:
Goals
Inflammatory Bowel Disease
Chart
Chart
Chart
Graphic
Graphic
Flow Diagram
Chart
Genetic susceptibility
Genetic susceptibility
NOD 2 (CARD 15)
NOD 2 (CARD 15)
CARD15 (NOD2) Colombel JF, Clinical Gastroenterology and Hepatology 1;5:2003
CARD15 (NOD2)
CARD15 (NOD2)
IBD Triggers
Environmental risk factors differ for CD and UC
Immune dysregulation and luminal antigens
IBD - Pathogenesis
Presence of fecal flora is necessary to develop colitis in animal models
Bad and good bacteria
Chart
Components of the mucosal barrier
Altered barrier function
Graphic
Cytokines
Cytokines mediate the complex interactions among cells* that fuel inflammation
Pathways of T-lymphocyte activation
Recruitment of effector cells into the inflammatory focus
Slide124
Major susceptibility loci
RFIPC
Translation from basic science to clinical medicine
Clinical presentation
UC-Symptoms
CD-Symptoms
Clinical presentation
Perianal disease
Extraintestinal manifestations
Extraintestinal manifestations
Growth Failure in Children with IBD
Chart
IBD vs IBS Clinical features
IBD - Diagnosis
Laboratory studies
IBD serologies
IBD serologies
Fecal calprotectin
IBD vs IBS Clinical and laboratory features
Diagnostic imaging
Crohn’s Disease - ileitis
Crohn’s Disease jejunitis
Ulcerative colitis
Diagnostic imaging - MRI
MRI Crohn’s Disease
Diagnostic imaging 99mTc-WBC scan
99mTc-WBC scan
Endoscopy in IBD
Endoscopy Crohn’s disease
Endoscopy Ulcerative colitis
Histology - Colitis
Histology Crohn’s disease
Diagnosis - Summary
Current therapeutic options in IBD
Chart
Chart
Budesonide
Aminosalicylates
Immunomodulators
6-MP in Pediatric IBD
Methotrexate
Summary current therapy for IBD
Immunomodulators
Infliximab
Infliximab
Infliximab
Infliximab
Infliximab
Emerging therapies - 2003
Biologics
Summary
IBD Future approaches to therapy

M. Susan Moyer, M.D.

Inflammatory Bowel Disease in 2003: From Genetic Predisposition to Biologic Therapies